FDA Lets Companies Deploy Generative AI Medical Devices Before Full Authorization

The U.S. Food and Drug Administration (FDA) has begun allowing Medicare patients to access generative AI-based medical devices before those devices complete the full marketing authorization process. This is happening under the TEMPO pilot, which has so far admitted four companies offering services ranging from hypertension management to AI-driven voice therapy for depression.

How TEMPO works

TEMPO, the Technology-Enabled Meaningful Patient Outcomes for Digital Health Devices Pilot, allows digital health companies to bring products into clinical use without obtaining standard FDA marketing authorization. The agency formally states that it will apply what is known as enforcement discretion to qualifying devices, meaning it deliberately declines to enforce premarket authorization requirements and investigational device regulations.

In exchange, companies must offer their technologies through the ACCESS model, run by the Innovation Center at the Centers for Medicare and Medicaid Services (CMS). ACCESS is a payment experiment in which Medicare funds technologies that help patients manage chronic conditions. Providers participating in the model can select devices qualified under TEMPO and incorporate them into patient care.

Who has joined so far

Dexcom was the first to join the pilot with its glucose monitoring program, selected on July 22, 2026. The second participant was Cadence, developer of HypertensionOS, AI-assisted software for managing hypertension medication under clinician oversight. They were joined by Limbic with its Unpacked app, which offers cognitive behavioral therapy delivered by a voice AI agent during scheduled phone calls under the supervision of licensed clinicians, and SonderMind with its SACA app, which supports reducing depression and anxiety symptoms in adult patients.

Limbic is the first fully AI-based mental health company to join the TEMPO program. In its model, a voice agent conducts scheduled therapy sessions, with each case supervised from start to finish by a licensed clinician.

The opportunity that clinical AI provides is to extend the judgment and reach of clinicians by safely delivering routine care within boundaries that they themselves set - Chris Altchek, CEO of Cadence

Clinical data and program scale

Cadence presented the FDA with a retrospective analysis covering more than 23,000 patients, showing an average blood pressure reduction of 7 over 5 millimeters of mercury after 30 weeks of using the software. This kind of real-world evidence is meant to form the foundation on which the FDA will build future rules for authorizing similar technologies.

The pilot is expected to grow in scale. The FDA has announced plans to admit up to ten manufacturers in each of the four clinical areas covered by the ACCESS model: early and advanced cardiovascular-renal-metabolic disease, musculoskeletal conditions, and behavioral health. That means as many as forty companies could join the program in the coming months.

Why the FDA is taking this approach

The agency has signaled for months that it does not yet have a ready framework for evaluating generative AI-based devices, which do not produce a single, repeatable output like traditional medical software but instead generate responses that vary depending on the context of the conversation with the patient. On August 18, 2026, the FDA's Center for Devices and Radiological Health (CDRH) published a discussion paper outlining possible approaches to regulating such devices and requested feedback on risk assessment, premarket review, post-market monitoring, and the use of third-party foundation models.

TEMPO is meant to give the regulator practical experience before these rules are finalized. Rather than waiting for the full, multi-year authorization pathway, the FDA is observing how AI systems perform in real-world care for Medicare patients and collecting data that is expected to feed into formal guidelines later.

To date, the FDA has not authorized a single fully generative AI-based medical device through the standard pathway. The pilot is therefore the first way this type of technology is reaching patients in the United States at any meaningful scale.

What it means for the market

For digital health companies, joining TEMPO means faster access to the market and to funding from Medicare, the largest payer in the U.S. healthcare system, without going through the full, costly marketing authorization process. For patients, it means exposure to AI tools that are formally still under regulatory review, though under clinician supervision and within defined therapeutic areas.

The program also points to a possible direction for AI regulation in medicine beyond the United States: an approach built on controlled pilots with real-world data, rather than waiting for a complete legal framework before allowing any technology into clinical use.